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Thomas E. Starzl 
In this paper I will address two subjects: the use of portal diver-
sion as a palliative treatment of some selected inborn errors of 
metabolism, and the actual provision of these patients with a 
missing enzyme by transplantation of a phenotypically normal 
new liver. Both are interesting new developments in surgery and 
pediatrics that, although controversial and not accepted initially, 
have been largely validated. 
Portal Diversion 
The basis for the use of portal diversion for metabolic as op-
posed to hemodynamic objectives was laid in the laboratory. I 
need not remind anyone here that the liver has a double blood 
supply. The hepatic artery usually provides 20-25% of the total 
hepatic blood flow, and the portal vein provides the remainder. 
The portal blood flow is derived from blood returning from 
various splanchnic organs, including the pancreas, spleen, stom-
ach, small intestine, and colon. Long before substances such as 
hormones were known, biologists of the 19th century concluded 
that this blood might contain specific and important components 
without which the liver could not survive. This was the accepted 
doctrine until an innocent little paper, one page long, upset the 
apple cart. In it, Nicholas Eck (1), a Russian military surgeon, 
described his experience with portacaval shunt in eight dogs. One 
of the animals died during the operation, six survived for a few 
days, dying of peritonitis or strangulation of the intestines and 
omentum, and one recovered completely and lived in the labora-
tory for two and one-half months. Or. Eck blamed his associates 
for the fact that the dog then ran away. Revealing his thoughts 
about the clinical implications of this operation, he wrote, "I am 
conducting these experiments with the purpose of clarifying some 
physiologic problems, to determine whether it would be possible 
to treat some cases of mechanical ascites by performing such a 
fistula." Perhaps Or. Eck overstated his case: he went on to say 
that, lithe main reason to doubt that such an operation can be 
carried out in human beings has been removed because it was 
established that the blood ... could be diverted without any 
danger to the body, and this by means of a perfectly safe opera-
tion." Despite the fact that he was confronted with an 88% mor-
tality rate, he realized that the Eck fistula was technically feasible. 
This was more than 100 years ago. 
The operation of portacaval shunt (Eck fistula), as it is usually 
done in the laboratory, consists of a side-to-side portacaval shunt 
above which the portal vein is tied off, converting the anastomosis 
to a completely diverting shunt (2). After such an operation, strik-
ing changes occur in the liver, the nature and rapidity of which 
have been completely understood in only the last 10-15 years. 
These changes affect the liver of all species so far studied, includ-
ing humans. 
The most striking morphologic change after portacaval shunt 
is acute atrophy of the hepatocytes to about half of their original 
size within less than a week. At the same time the livers accumu-
late fat and develop multiple and dramatic ultrastructural changes. 
The most specific change is depletion of the rough endoplasmic 
reticulum and its polyribosomes. Semiquantitative morphometric 
analysis shows that the rough endoplasmic reticulum is reduced 
to about one-fourth of its original volume. In addition, glycogen 
granules are depleted, and the mitochondria develop nonspecific 
abnormalities. 
Until recently the explanation of the changes caused by Eck 
fistula was not known. Rather than detail the tortuous pathways 
we followed to determine the causes, I will skip to the final and 
crucial experiment (2, J), in which we found that the changes 
caused by portacaval shunt in dogs could be prevented by the 
infusion of insulin into the tied-off central portal vein. The experi-
ment was quite simple. We ligated the right and left portal veins 
in the hilum, but left the insulin-infusion catheter in one of the 
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main portal branches. One could compare the liver lobes that 
were directly infused with insulin with those that were not. Thus, 
we looked not only at the potential protective effect in the insulin-
infused lobes, but also at whether there was a carryover effect 
on the side not receiving insulin. There was no carryover protec-
tion. On the treated liver side, this simple procedure of infusion 
of insulin completely prevented the involutional changes caused 
by portacaval shunt. We concluded that many or most of the 
changes caused by portacaval shunt were due to endogenous insu-
lin bypassing the liver. This work in experimental pathology was 
the product of K. A. Porter of St. Mary's Hospital and Medical 
School in London, with whom we have collaborated for many 
years (3-7). 
So far, I have discussed only the striking morphologic changes 
caused by portacaval shunt. In addition, portal diversion causes 
profound changes in metabolism, the following example of which 
is especially relevant to clinical applications. As we have demon-
strated in dogs and humans, cholesterol synthesis is greatly de-
creased in livers deprived of a portal blood supply (8). Bilheimer 
and Brown of Southwestern University, Dallas, showed the same 
thing in a patient upon whom I had operated. 
Glycogen Storage Disease 
In 1963, armed with some of the above information, we began 
a series of operations on patients with glycogen storage disease 
(6, 7) (Table 1). The patients had Types I, III, and VI disease, 
mostly Type I (glucose-6-phosphatase deficiency). After the oper-
ation there was a substantial amelioration of the metabolic pertur-
bations of the patients. Those with Type I disease all had hyper-
lipidemia, which was alleviated immediately. Abnormalities of 
Table 1. Inborn Errors Treated with Portacaval Shunt 
Disease 
Glycogen storage 
Hyperlipidemia 
ai-Antitrypsin 
deficiency 
No. of 
cases 
11 
7 
3 
Lmglh of 
folltnoup, years 
2-2.0 
2-6.5 a 
1K~R 
• The xanthomas shrank or disappeared. The serum cholesterol decreased to 35-68% of the pre-
portacaval shunt value. In five of the seven, the cardiovascular status stabilized. 
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coagulation and uric acid metabolism improved. The most striking 
occurrence was a growth spurt in these patients, who were all 
stunted. After portacaval shunt, the patients grew at the rate of 
0.5-1 cm a month, during the first postoperative year. These 
growth spurts could be seen and documented by roentgenographic 
techniques of bone assessment. One child experienced such major 
growth that her bone age increased from 3.5 to seven years in 
the first 11 postoperative months. The bones lengthened and be-
came mineralized, and new growth centers appeared in the wrists 
and elsewhere. 
The full explanation of these striking effects is not yet clear. 
The blunted peripheral insulin response to a glucose meal, which 
is typical of Type I disease, was greatly increased after the shunt. 
Insulin being a powerful growth factor, perhaps the increased 
insulinemia was a factor in the growth. Not surprisingly, the one 
symptom that was not promptly relieved by portacaval shunt 
was the nocturnal hypoglycemia found in most patients. 
One of my associates on this project, Dr. Harry Greene, later 
moved to Vanderbilt and introduced there the very interesting 
alternative form of therapy of continuous enteral alimentation 
(9). He provided continuous overnight feeding by nasogastric tube 
or by a gastrostomy and showed that many of the same benefits 
of portacaval shunt could be obtained thereby.1 Consequently, I 
now recommend that continuous alimentation be carried out as 
the first option, with portacaval shunt reserved for a back-up 
treatment. The treatment of glycogen storage disease has been 
truly revolutionized in the last 20 years, first by portal diversion 
and then by continuous alimentation. 
Familial Hypercholesterolemia 
Familial hypercholesterolemia is a disease for which there is 
no such alternative (Table 1). Portacaval shunt often is the only 
effective form of treatment. The first patient treated was a nine-
year-old girl with homozygous Type II hyperlipidemia, who had 
a massive myocardial infarction six weeks before portacaval shunt 
was performed (8, 10). She was taken to the operating room from 
I Ed. nof~: Dr. Greene discussed this technique in the preceding volume in this series, 
Human Nutrition: Clinica/ and Biochmlica/ AsptCfs, P. J. Garry, Ed., Am. Assoc. Clin. Chem., 
Washington, DC, 1981, pp 383-397. 
the Intensive Care Unit at the University of Colorado, from which 
it was apparent that she would never emerge (8, 10, 11). 
Homozygous familial hypercholesterolemia is characterized by 
deposits of xanthomatous material in the tendons, the skin, the 
coronary arteries, and the valves of the heart. The cardiovascular 
problems become so severe that these patients almost never live 
into or beyond the teen years. They often die of myocardial infarc-
tions before puberty, and this, indeed, was the course this child 
was following (10). After portacaval shunt, her serum cholesterol, 
which had been about S.OO giL, decreased, and within six months 
it almost reached a normal concentration (8). We could easily 
see what happened to the xanthomatous lesions on her hands 
and other superficial areas, but comparable changes were taking 
place inside her body. The excrescences shrank and disappeared 
over a period of 16 months, leaving only faint skin stains. The 
child died about 18 months postoperatively, from a complication 
of her previous myocardial infarction. She developed a fatal ar-
rhythmia when coming home from schooL 
The serum cholesterol concentrations of the other six patients 
we treated, five children and one adult, also decreased. A summary 
of the results in the first seven hyperlipidemia cases after two 
to 6.5 years' survival is given in Table 1. The xanthomas all shrank 
or completely disappeared. The serum cholesterol invariably de-
creased in parallel with decreases in low-density lipoproteins. The 
cardiovascular disease, interestingly enough, improved or stabi-
lized in most patients as the cutaneotendinous lesions disappeared. 
In some of the cases, we documented by serial catheterizations 
a reduction in the gradient of aortic stenosis or improvement in 
coronary artery disease. 
a-Antitrypsin Deficiency 
Perhaps this third inborn error of metabolism can also be palli-
ated with portal diversion. aI-Antitrypsin deficiency is an inborn 
error that follows genetic rules, but the exact reason for the mani-
festations of this disorder is really not known. Although aI-anti-
trypsin is synthesized by the liver, its structure is sufficiently 
abnormal that it cannot be transported; thus, it accumulates in 
the liver and probably is responsible for hepatic injury. We have 
treated three patients with portacaval shunt and have followed 
them for 1.5 to more than five years. 
These patients have been remarkably stable. In two of them, 
we biopsied the liver at the time of the shunt and one to two 
years later. In one case, the amount of at-antitrypsin in the hepa-
tocytes had actually decreased, as determined by morphometric 
analysis; and in the other, the amount remained the same. Perhaps 
with the depletion of rough endoplasmic reticulum the synthesis 
of the abnormal at-antitrypsin was reduced without a commensu-
rate decrease in the excretion of this alpha-globulin through the 
hepatocytes. If so, a favorable metabolic equilibrium would have 
been established that could, in a very subtle way, allow the disease 
to be more compatible with long life. However, these trials are 
still highly experimental, and we are not recommending portal 
diversion to treat this liver disease. 
Liver Transplantation 
Liver transplantation offers a more direct approach to enzyme-
deficiency disease, or inborn errors of metabolism. For any of 
the liver-based inborn errors I will mention here, transplantation 
of a phenotypically normal liver supplies or probably supplies 
the missing enzyme. It is a simple concept. Phenylketonuria (PKU) 
for example, is known to be a liver-based inborn error, and so, 
by definition, is curable by liver replacement. Obviously, however, 
less drastic approaches are preferable. 
Examples also can be found in laboratory animals. Several years 
ago a group at the Mayo Clinic reported experiments in which 
Dalmatian dogs, which suffered from gout, were given livers from 
mongrel donors and were cured of their gout (12). The defect 
in uric acid metabolism was eliminated. 
Because the concept is so childishly simple, I do not think there 
is any need to dwell on it. The main prerequisite to exploiting 
the possibilities of liver transplantation has been the need to de-
velop better ways of preventing liver rejection. 
Recent developments in immunosuppression have made possi-
bl~ efforts considered unrealistic only a few years ago. The key 
factor in these new expectations is a new drug called cyclosporin 
A (cyclosporine) (13), first used in clinical trials in kidney trans-
plantation (14, 15). 
Before cydosporin A was available, the most important devel-
opment in immunosuppression occurred about 20 years ago with 
the combined use of azathioprine (Imuran) and prednisone. With 
these drugs, kidney transplants became possible in other than 
twin recipients (16, 17). When, as often happened, transplanted 
kidneys began to be rejected after a few days or a few weeks, 
augmented steroid therapy allowed reversal of rejections. We also 
noticed that these patients subsequently developed what we called 
(perhaps incorrectly) partial tolerance. In many cases, the amount 
of immunosuppression could later be decreased. With that advan-
tage, the patients were able to return horne, have babies, go to 
the movies, and in general return to normal society. 
This work (16) was done with Torn Marchioro (now at the 
University of Seattle in Washington) and Bill Waddell (at the 
University of Colorado). The technique of double-drug therapy 
has become the worldwide standard method of immunosuppres-
sion. Unfortunately, it was an achievement of which I personally 
became ashamed, because it was so limited, as illustrated by the 
results for nearly 5000 primary (first-time) cadaveric kidney 
transplantations in 105 centers from 1971 to 1976. The six-month 
graft survival was only 55% and the one-year survival 45% (18). 
Thus more than half of the patients given cadaveric kidneys were 
losing them within the first postoperative year. Moreover, the 
penalties, even with "success," were sometimes unacceptable and 
included cosmetic deformity from the steroids, infections, an in-
creased incidence of de novo malignancies, bone disease, gastroin-
testinal disorders, and cataracts. Consistently good results could 
be obtained only with transplantation from living, related donors. 
Attempts to improve the outlook with antilymphocyte globulin, 
thoracic duct drainage, and tissue matching resulted in only small 
gains. 
It was clear that the situation could not really change unless 
new drugs were developed. Such a new agent, cyclosporin A, sur-
faced in 1976 in a paper by Borel et al. (13). Cyclosporin A is 
an extract of two fungi. The most potent immunosuppressive 
agent yet described, it has no bone marrow toxicity. Until its 
development there had been no immunosuppressive drug, exclud-
ing steroids, that did not with chronic use depress the bone mar-
row. 
In 1978, cyclosporin A was released for clinical trial to two 
groups in England-one at Cambridge, the other (for bone marrow 
transplantation) at the Royal Marsden Cancer Hospital near Lon-
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don. The first reports on whole-organ transplantation, from Calne 
et al. (14, 15) of Cambridge in 1978 and 1979, were mixed. The 
good news was that many cadaveric kidney recipients treated 
with cyclosporin A never required steroid therapy. The bad news 
was that three of the first 33 patients developed lymphomas. In 
addition, the mortality from infection was high, and one in three 
of the patients died. Nonetheless, the Cambridge group recom-
mended using cyclosporin A as the sole immunosuppressive agent. 
Cyclosporin A was released in the United States in late 1..979, 
to two centers-the Peter Bent Brigham in Boston, and to us at 
the University of Colorado. We quickly learned that for optimal 
use cyclosporin A needed to be used with steroids, and not as a 
sole immunosuppressive agent as the English had recommended. 
We recommended (19-21) that, in addition to cyclosporin A, 
adults be given a five-day course of rapidly decreasing daily doses 
of steroids, e.g., prednisone, starting at 200 mg/day and decreasing 
to 20 mg daily maintenance, as the subsequent course permitted. 
This was a revolutionary development, because decreasing steroids 
to such levels, when combined with azathioprine, had required 
months, not days. 
The control of rejection with this combination of cyclosporin 
A and steroids has been really quite amazing. The actual one-
year survival of cadaveric kidney grafts, even during a learning 
phase, was 80% (21). That is a stunning figure, almost twice as 
good as the graft survival after conventional immunosuppression. 
At the University of Pittsburgh, where I now work, graft survival 
has been even higher. The combination of cyclosporin A and 
steroids is almost a fail-safe method of immunosuppression. 
Given the background that has been developed with the kidney, 
there has been a powerful movement to apply the same techniques 
for the transplantation of other organs. For the first time, the 
ability to perform hepatic transplants safely and relatively reliably 
is in sight. The procedure usually used for liver transplantation 
is organ replacement. The diseased liver is removed and a cadaveric 
organ is put in. The new liver can be preserved for 6 to 12 h if 
necessary, by infusing with cold solutions. All of the structures 
entering and leaving the graft are installed as anatomically normal 
as possible. For chemists, sewing in a liver must seem naive or 
anti-intellectual, which it probably is, but the results can be emo-
tionally gratifying. The longest survival after liver transplantation 
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has been of a little girl whose operation was 12 years ago when 
she was four. 
The problem with liver transplantation throughout the years 
has been that the undertaking was dangerous and unpredictable. 
Only 35 to 40% of the patients could be expected to survive 
through the first postoperative year, a situation that has changed 
with the use of cyclosporin A. The last year I was in Denver, 
we considered 14 patients for liver transplantation under the same 
cyclosporin-steroid therapy that we had developed for kidneys. 
Two patients died on the operating table. Of the other 12, 11 
(92%) lived for at least a year. Even including the two operative 
deaths, the one-year survival rate in those liver recipients was 
almost 80% (20). Similar results have been obtained at the Univer-
sity of Pittsburgh. 
Even in the early days of liver transplantation, the potential 
value of this technique for treating inborn errors was obvious. 
When liver replacement was first carried out in humans, there 
were changes in the recipient's alpha-protein phenotypes, hapto-
globin, and group-specific components. These and subsequent ob-
servations of other phenotypes proved that the metabolic specific-
ity of the new organ remained that of the donor for as long as 
the graft functioned (22). 
For completely understood inborn errors, this expectation has 
been realized on a number of occasions (Table 2). The most experi-
ence (eight cases) has been with aI-antitrypsin deficiency (23). 
After orthotopic liver transplantation, the Pi type of the recipient 
has become that of the donor and the abnormally low values of 
serum aI-antitrypsin have increased to normal values. After liver 
transplantation, the accumulation of aI-antitrypsin in a homograft 
has never been seen. 
Another disorder that has been cured metabolically by liver 
replacement in spite of its unknown pathogenesis is Wilson's dis-
ease (Table 2) (24), characterized by widespread accumulation 
of copper in tissues. We have treated two patients with orthotopic 
liver transplantation. One died six years after the operation be-
cause of biliary tract complications that could not be rectified. 
The other is .still well after more than 10 years. Both recipients 
underwent a protracted decoppering process, as documented by 
urine copper excretion. Progress could be monitored as the Kayser-
Fleischer rings of the cornea receded and disappeared. Serum ceru-
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Table 2. Inborn Errors of Metabolism Corrected by Liver Transplantation 
No. of 
DistllSt CllSts Enzyme defect Longtst sum val 
aI-Antitrypsin 8 Unknown 5 yr. 
deficiency 
Wilson's disease 2 Unknown 10.5 yr. 
Type IV glycogen 1 Amylo-1A -transglucosi- 3 mo. 
storage disease dase (branching 
enzyme) 
Tyrosinemia 2 p- H ydroxyphenylpyruvic 6 mo. 
acid oxidase 
Niemann-Pick 1 Sphingomyelinase 1.5 yr. 
disease a 
Crigler-Najjar 1 Glucuronyl-transferase 1 mo. 
syndrome b 
• Patient treated by Dr. PielTe Oilloze, Notre Dame HospiW, Montreal. 
• Treated by auxiliary liver transplantation (see text); all other transplants were liver replacements. 
loplasmin, which is almost always very low in patients with Wil-
son's disease, was restored to normal within a few days after 
transplantation and has remained so for more than 10 years in 
our second patient. 
At least four other inborn errors with known and specific en-
zyme deficiencies have been treated by liver transplantation (Table 
2). In a child with Niemann-Pick disease (25), a metabolic cure 
was obtained after orthotopic transplantation, but the pre-existing 
neurologic injury was not ameliorated and eventually was indi-
rectly responsible for death. Children treated by us for Type IV 
glycogen storage disease and congenital tyrosinemia (26) died 
soon after transplantation (Table 2), but complete studies in the 
latter patient showed that essentially normal tyrosine metabolism 
had been achieved (26). 
The foregoing experience was with liver replacement. Seven 
years ago, we attempted to treat a two-year-old child with Crigler-
Najjar syndrome by transplanting an auxiliary liver. With this 
disease, a nearly complete absence of hepatic glucuronyl transfer-
ase makes impossible the conjugation of bilirubin by the liver. 
Yet, all other measures of liver function are normal, making re-
moval of the original liver not entirely desirable. We transplanted 
an auxiliary liver to the right paravertebral gutter, taking its he-
patic arterial supply from the aorta, and anastomosing the portal 
vein end-to-end to the transected recipient portal vein. Outflow 
was established by anastomosing the end of the graft intrahepatic 
inferior vena cava to the side of the recipient vena cava. The 
graft and recipient gallbladders were also anastomosed. The auxil-
iary graft produced bile immediately and by the following morn-
ing the deeply jaundiced sclera (serum bilirubin 500 mg/L) had 
become white and the bilirubin was normal. Unfortunately, the 
portal vein and hepatic artery thrombosed several days later, and 
the auxiliary liver was removed. The child was returned to the 
previous treatment with plasmapheresis and died several months 
later of kernicterus. 
The results shown in Table 2 were obtained in an era when 
conventional immunosuppression was used (27). "Metabolic engi-
neering" in the new era of better immunosuppression with cyc1o-
sporin A and steroids will become increasingly common and suc-
cessful. At the University of Pittsburgh, we have already used 
liver transplantation to treat patients with al-antitrypsin defi-
ciency, subacute Wilson's disease, tyrosinemia, Type I glycogen 
storage disease, and the sea blue histiocyte syndrome. With the 
improved new immunosuppressive therapy, these kinds of dis-
eases will be effectively treated with increasing frequency. 
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Discussion 
Q: What is the mechanism of cyclosporin A? 
DR. STARZL: Jean Borel thought that the drug was a relatively 
specific inhibitor of activated T lymphocytes. That idea seems 
to be holding up in various in vitro experiments. Also in experi-
mental animals and perhaps in humans, part of the population 
of specific suppressor cells seems to be at least passively preserved. 
If these two suggestions hold up, and they can be put together, 
they would explain the great safety with which cyclosporin A 
can be used. George Santos of Johns Hopkins is convinced the 
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suppressor cell preservation is important, and several others agree 
with him. 
DR. GREENBLATT: When you compare cyc1osporin A with some 
of the other immunosuppressives, do you notice any difference 
in the virus infections? 
DR. STARZL: Infections have been less, about one-fifth of what 
they were with conventional therapy. In Minnesota they found 
less fungal and almost no bacterial infection with cyc1osporin 
A. At a Cambridge conference in September, A. G. Bird of Bir-
mingham, England, reported six lymphomas. The lymphomas had 
occurred in patients who had an Epstein-Barr virus infection. 
The evidence that this virus caused lymphoma is circumstantial 
in some cases, but direct and incontrovertible in others. 
Q: Does the report of an 8-14 translocation in these cases 
suggest that there is another event besides the cytogenetic event? 
DR. STARZL: Yes. The present hypothesis is that the Epstein-
Barr infection plays a background role in the sense of creating 
a proliferating population, and that the cytogenetic transformation 
is the second necessary condition. Incidentally, this kind of patho-
genesis is not unique to immunosuppression under cyclosporin 
A. It is probable that the same events explain many of the lympho-
mas under conventional therapy with azathioprine and predni-
sone. 
Q: Are there any hematopoietic ramifications following liver 
transplantation? Do you see any new blood types or blood prod-
ucts that are related to the liver? 
DR. STARZL: Yes, two of the early protein phenotypes that 
were demonstrated to change were haptoglobin and group-specific 
component. Once these alpha-globins had changed phenotypes, 
the change persisted for the life of the patient. Since then several 
other phenotypes have been studied and documented in a paper 
by Alper et al. (22). Basically they are not too important. 
Q: With liver transplantation for Niemann-Pick disease, is 
it realistic to hope that the extrahepatic tissues will receive a 
supply of the missing enzyme? I ask because I wonder if the 
macromolecules can be cleared from the central nervous system? 
DR. STARZL: The patient I mentioned did not recover from 
his pre-existing neurologic status, and that was the reason for 
death a year and a half later. The Montreal physicians who studied 
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the patient with Niemann-Pick disease reported the development 
of demonstrable sphingomyelinase in the peripheral blood. 
We do know that the neurologic disorder of Wilson's disease 
can be strikingly reversed with provision of a new liver, but of 
course that is a completely different disease. 
Q: The question of whether the products of the new liver 
can cross the blood-brain barrier and be able to mobilize the 
lipid material is extremely important. The possibility that this 
may occur is a very exciting one, but unproven. 
DR. 5TARzL: I hope that this occurs. The degree of reversal 
that can occur in a disorder such as Wilson's disease is really 
quite striking. 
Q: Could you comment on the susceptibility to infectious 
disease of patients under cyclosporin A? 
DR. 5TARzL: The incidence of all kinds of infections is dis-
tinctly less under cyclosporin A than with conventional immuno-
suppression. Our preliminary impression is that bacterial and fun-
gal infections have become extremely uncommon, occurring at 
about one-fifth the rate of our past experience. Patients under 
cyclosporin A do have a significant incidence of virus infections, 
but the incidence is still only half of that observed with azathio-
prine-prednisone therapy. Incidentally, the same kind of data is 
being generated by investigators of the University of Minnesota. 
Q: What are the side effects of cyclosporin A? 
DR. 5TARZL: The incidence of lymphoma has been no greater 
per month of graft survival and function than with conventional 
immunosuppression. The most specific side effect of cyclosporin 
A is nephrotoxicity. However, the guidelines for management 
of this have been well worked out in Colorado and in Pittsburgh 
(20, 21). In essence, one must determine what the dose ranges 
are in which cyclosporin A toxicity can be expected and reduce 
the dose when there is a suspicion of drug injury to the kidney. 
The renal impairment is quickly responsive to dose reductions. 
So far, there have been no specific and diagnostic lesions that 
can be identified by conventional pathologic studies. Probably 
the nephrotoxicity causes proximal tubular damage. At one time, 
some of the European workers thought that they were seeing 
abnormal giant mitochondria in the renal tubules, but this has 
not been confirmed. 
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One of the unusual opportunities which we have had in the 
combined Colorado-Pittsburgh experience is to be able to study 
renal function in liver recipients and to study hepatic function 
in kidney recipients. By so doing, we have been able to eliminate 
the confusion that is inevitable when one is looking for organ 
toxicity with the organ that has just been transplanted. To put 
it more simply, it has been exceptionally difficult in renal graft 
recipients to study renal toxicity, but it has been simple to study 
renal toxicity in patients with liver transplants. The essence of 
management is dose manipulation. 
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